Skip to content

Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults

Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05830942
Enrollment
120
Registered
2023-04-26
Start date
2024-04-15
Completion date
2027-04-30
Last updated
2026-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Frail Elderly, Mobility Limitation

Brief summary

Declines in cognitive function and walking function are highly intertwined in older adults. A therapeutic approach that combines complex (cognitively engaging) aerobic walking exercise with non-invasive electrical brain stimulation may be effective at restoring lost function. This study tests whether electrical stimulation of prefrontal brain regions is more beneficial than sham stimulation.

Detailed description

Efficacy of transcranial direct current stimulation (tDCS) combined with complex (cognitively engaging) walking exercise in older adults. The primary outcome measures are executive function (computer-based assessment battery) and complex walking function (speed on an obstacle negotiation task). This will be a two-site trial conducted at the University of Florida (lead site) and Brooks Rehabilitation Hospital, which is necessary to achieve enrollment targets and will allow us to develop a multi-site research infrastructure for a future Phase 3 multi-site trial. The study will enroll up to 120 older adult women and men, who exhibit mild to moderate decline of executive function. All experimental groups will receive the same complex walking intervention, which will focus on use of cognitively engaging tasks such as obstacle crossing, accurate foot placement, and walking on complaint surfaces. Each session will consist of 30 minutes of walking. For tDCS, the active treatment group will receive 20 minutes of 2mA tDCS over prefrontal regions F3/F4 ("treatment group"). The second group is a sham control group. tDCS will be delivered simultaneously with complex walking exercise for 18 sessions over a 6-week period. Assessments will be conducted at baseline, post intervention (within one week), and 12 weeks post-intervention.

Interventions

BEHAVIORALWalking Exercise

aerobic walking exercise using complex (cognitively engaging) walking tasks

DEVICEPrefrontal Active tDCS

20 minutes of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session

DEVICEPrefrontal Sham tDCS

30 seconds of 2 milliamp transcranial direct current stimulation (tDCS) of prefrontal regions, delivered at each session

Sponsors

University of Florida
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 65+ * Objective executive function decline, based on standardized cognitive assessments. * Subjective cognitive decline, based on the question: "During the past 12 months, have you experienced confusion or memory loss that is happening more often or getting worse?" * Ability to walking independently for 6 minutes (use of cane permitted)

Exclusion criteria

* Major cognitive disorder that interferes with independence * Percentile score less than 10th percentile on standardized cognitive assessments * Medications that are thought to influence tDCS neuroplasticity. * Contraindications to tDCS or MRI.

Design outcomes

Primary

MeasureTime frameDescription
walking speed for obstacle task negotiation taskbaseline, post-intervention (an average of 6 weeks after baseline), follow-up (an average of 12 weeks after post-intervention)change in walking speed from baseline to post intervention (or follow-up) timepoint
score on test of executive functionbaseline, post-intervention (an average of 6 weeks after baseline), follow-up (an average of 12 weeks after post-intervention)change in score from baseline to post intervention (or follow-up) timepoint

Countries

United States

Contacts

CONTACTDavid J Clark, ScD
davidclark@ufl.edu352-376-1611
PRINCIPAL_INVESTIGATORDavid J Clark, ScD

University of Florida

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026